NIH has recently published a number of funding opportunity announcements for the Rapid Acceleration of Diagnostic (RADx). One of these initiatives, RADx-rad, aims to support new, non-traditional approaches, including rapid detection devices and home-based testing technologies, that address current gaps in COVID-19 testing. Specific funding opportunities are listed below. For the full list of RADx-RAD initiatives please visit the NIH website, found here.
Chemosensory (smell/taste) Testing as a COVID-19 Screening Tool – for questions, please contact Amanda Melillo, amanda.melillo@nih.gov
Chemosensory Testing as a COVID-19 Screening Tool (U01 Clinical Trial Optional)
Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions for Chemosensory Testing as a COVID-19 Screening Tool
Novel Biosensing for Screening, Diagnosis and Monitoring of COVID-19 From Skin and The Oral Cavity – for questions please contact, Orlando Lopez, orlando.lopez@nih.gov
Additionally, NIDCR is signed onto the following RADx-rad Initiatives:
Emergency Awards: Exosome-based Non-traditional Technologies Towards Multi-Parametric and Integrated Approaches for SARS-CoV-2 (U18 Clinical Trial Not Allowed) – for questions please contact, Preethi Chander, preethi.chander@nih.gov
Emergency Awards: RADx-RAD Multimodal COVID-19 surveillance methods for high risk clustered populations (R01 Clinical Trial Optional) – for questions please contact Dena Fischer, dena.fischer@nih.gov